不同剂量沙库巴曲缬沙坦治疗慢性心力衰竭急性加重患者的临床疗效OA

Objective:To investigate the clinical effect of different doses of sacubitril/valsartan as adjunctive therapy in patients with acute exacerbation of chronic heart failure(AECHF).Methods:A total of 80 patients with AECHF admitted to our hospital from March 2021 to March 2024 were selected as the study participants.All patients were randomized by the random number table method into a low-dose group(sacubitril/valsartan sodium tablets 100 mg/day)and a high-dose group(sacubitril/valsartan sodium tablets 200 mg/day),with 40 patients in each group.After 3 months of continuous treatment,cardiac function indicators[left ventricular ejection fraction(LVEF),left ventricular posterior wall thickness(LVPW),and diastolic interventricular septal thickness(IVST)],myocardial injury markers[creatine kinase-isoenzyme(CK-MB),N-terminal pro-B-type natriuretic peptide(NT-proBNP),and cardiac troponin T(cTnT)],quality of life[Minnesota Living with Heart Failure Questionnaire(MLHFQ)score],clinical efficacy,and adverse reactions were compared between the two groups.Results:After treatment,LVPW,IVST,CK-MB,NT-proBNP,and cTnT decreased in both groups and were lower in the high-dose group than in the low-dose group(P<0.05),whereas LVEF and MLHFQ scores increased in both groups and were higher in the high-dose group(87.50%)than in the low-dose group(67.50%,P<0.05).The total overall clinical response rate was higher in the high-dose group than in the low-dose group(P<0.05).The total incidence of adverse reactions did not differ significantly between the two groups(P>0.05).Conclusion:The high-dose sacubitril/valsartan showed a greater effect in improving cardiac function,reducing myocardial damage,and enhancing quality of life compared to the low-dose group.Moreover,its adverse reactions were similar to those of the low-dose sacubitril/valsartan regimen.